<DOC>
	<DOC>NCT02978599</DOC>
	<brief_summary>Single-center, outpatient, randomized, double-blind, placebo-controlled, 3-treatment-phase, cross-over study to evaluate the safety, tolerability and efficacy of two oral doses of AVL-3288 each compared to placebo, in patients with schizophrenia.</brief_summary>
	<brief_title>Clinical Trial of AVL-3288 in Schizophrenia Patients</brief_title>
	<detailed_description>This study will be in 24 non-smoking outpatients with schizophrenia or schizoaffective disorder. Subjects will complete three treatment phases, each involving 5 straight days of taking AVL-3288 (10 mg or 30 mg study drug or placebo) followed by a 16 day washout period in which subjects do not take the study drug to ensure that the drug is completed eliminated from the body before the next phase.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>DSMV diagnosis of schizophrenia or schizoaffective disorder RBANS Total Scale Score &gt;65 Willing to provide informed consent Medically stable for study participation Taking an antipsychotic medication other than clozapine at a stable dose for at least 4 weeks Judged clinically not to be at significant suicide or violence risk Substance abuse (excluding nicotine) within last 90 days ECG abnormality that is clinically significant Current clozapine use Participation in a study of investigational medication/device within 4 weeks Pregnancy, lactation, or lack of use of effective birth control Active tobacco use Presence or positive history of significant medical or neurological illness, including cardiac illness, WBC &lt;3500/mm3, absolute neutrophil count &lt;1500/mm3, ALT or AST values &gt;1.5 times upper limit of normal. Hemoglobin less than 130 g/L (13 g/dL) in males or 120 g/L (12 g/dL) in females or known HIV + Contraindication to MRI scanning, including metal implants or claustrophobia Medicinal patch, unless removed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>